What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

MapLight Therapeutics, Inc. MPLT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bristol-Myers SquibbBMY

$46.37B+0.8%

Neurocrine BiosciencesNBIX

$2.82B+11.3%

Acadia PharmaceuticalsACAD

$3.06B+3.7%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$527.06M—

MeiraGTx Holdings plcMGTX

$820.02M+5.1%

Alto NeuroscienceANRO

$471.22M+61.0%

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's additional paid-in capital?: MapLight Therapeutics, Inc. (MPLT) reported additional paid-in capital of $821.9M in Q1 2026.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.